Loading
A phase 2 trial of FK-PC101 in prostate cancer, run by Cellvax Therapeutics Inc, now recruiting.
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer is a phase 2 interventional study registered as NCT06636682 by Cellvax Therapeutics Inc, with 100 participants planned, started 2024-10-14 and due to reach its primary completion in 2027-02-02. Interventions recorded: FK-PC101 and Standard of Care (SOC).
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.